EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

02/11	EvoNext Holdings Enters Deal to Merge with Ascend Sport Technology	MT
12/10	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT

Market Cap	1.68Cr 2.05Cr 1.83Cr 1.53Cr 2.87Cr 193.96Cr 2.94Cr 20Cr 8.07Cr 102.37Cr 7.69Cr 7.52Cr 324.47Cr	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	1.09Cr 1.33Cr 1.19Cr 98.97L 1.86Cr 125.79Cr 1.91Cr 13Cr 5.23Cr 66Cr 4.98Cr 4.88Cr 210.43Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	62.03%	Yield 2024 *	-	Yield 2025	-

02/11	EvoNext Holdings Enters Deal to Merge with Ascend Sport Technology	MT
12/10	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT
12/10	Ascend Sport Technology AG signed a binding transaction agreement to acquire EvoNext Holdings SA for approximately CHF 500 million in a reverse merger transaction.	CI
30/09	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
30/09	EvoNext Holdings' H1 Net Loss Widens; Financial Income Up	MT
18/08	Evonext Holds Talks to Take Ascend Sport Public	CI
18/08	EvoNext in Advanced Negotiations with Ascend Sport Technology for Reverse Merger	MT
17/08	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
17/08	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
30/04	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/25/21	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/25/25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25/25/25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI

02/11	EvoNext Holdings SA and Ascend Sport Technology AG sign merger agreement	EQ
12/10	EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement	EQ
30/09	EvoNext Holdings SA publishes half-year report 2026	EQ
17/08	EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG	EQ
20/05	EvoNext : Minutes of Annual General Meeting 2026	PU

02/11	EvoNext: fusion avec Ascend Sport Technology actée
02/11	Evonext und Ascend unterzeichnen Fusionsvertrag
12/10	Ascend Sport Technology sbarcherà in borsa
12/10	Sporttech-Firma Ascend will durch Fusion mit EvoNext an Schweizer Börse
12/10	Evonext und Ascend Sport einigen sich auf Fusion

ARPIDA Share Price Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news: ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	27/03/2025
Gianluca Ferrari CHM	Chairman	-	27/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.43%	-7.34%	+36.10%	+58.44%	6.22TCr
ARGENX SE	+0.61%	+0.77%	+11.13%	+69.42%	5.49TCr
LONZA GROUP AG	+0.62%	+2.58%	+20.96%	+98.18%	5.53TCr
IQVIA HOLDINGS INC.	+1.54%	-3.23%	+22.86%	+33.25%	4.26TCr
BEONE MEDICINES AG	-1.71%	-2.80%	+14.09%	+93.60%	4.11TCr
REVOLUTION MEDICINES, INC.	+3.43%	+4.70%	+228.61%	+779.81%	4.03TCr
GENMAB A/S	+0.57%	+24.09%	+99.46%	+84.11%	3.31TCr
CELLTRION, INC.	-1.09%	-0.05%	+13.55%	+45.35%	3.26TCr
INSMED INCORPORATED	-3.32%	+10.86%	-43.47%	+323.64%	2.4TCr
Average	-0.17%	+3.75%	+44.81%	+176.20%	4.29TCr
Weighted average by Cap.	-0.10%	+2.11%	+45.28%	+159.57%

	2024	2025
Net sales	-	-
Net income	10.44L 12.72L 11.36L 9L 17.8L 12Cr 18.25L 1.25Cr 50.12L 6.36Cr 47.74L 46.72L 20Cr	-7L -8L -7L -6L -11.13L -7.53Cr -11.41L -77.91L -31.34L -3.98Cr -29.85L -29.21L -13Cr
Net Debt	-67.53L -82.29L -73.52L -61.33L -1.15Cr -78Cr -1.18Cr -8.06Cr -3.24Cr -41Cr -3.09Cr -3.02Cr -130.41Cr	-59.06L -71.96L -64.29L -53.64L -1.01Cr -68Cr -1.03Cr -7.05Cr -2.84Cr -36Cr -2.7Cr -2.64Cr -114.04Cr

End-of-day quote Swiss Exchange
- ^CHF	-